Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression

Cancers

Giulia Corrao¹  BarbaraAlicja Jereczek-Fossa¹  Claudia Proto²  ChiaraCarlotta Pircher²  AlessandroDe Toma²  MarinaChiara Garassino²  Arsela Prelaj²  Giacomo Massa²  Filippode Braud²  Giuseppe Lo Russo²  Giulia Galli²  Roberto Ferrara²  Valentino Martelli³  SaraElena Rebuzzi³  Carlo Genova⁴ 

[1] Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, via Ripamonti 435, 20141 Milan, Italy;Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, via Giacomo Venezian 1, 20133 Milan, Italy;Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genova, Italy;UO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132 Genova, Italy;

关键词: non-small cell lung cancer;    oligoprogression;    immune checkpoint inhibitor;    immunotherapy;    local therapy;    resistance;   

DOI  :  10.3390/cancers13061300

来源: DOAJ

【 摘 要 】

First-line immune-checkpoint inhibitor (ICI)-based therapy has deeply changed the treatment landscape and prognosis in advanced non-small cell lung cancer (aNSCLC) patients with no targetable alterations. Nonetheless, a percentage of patients progressed on ICI as monotherapy or combinations. Open questions remain on patients’ selection, the identification of biomarkers of primary resistance to immunotherapy and the treatment strategies to overcome secondary resistance to first-line immunotherapy. Local ablative approaches are the main therapeutic strategies in oligoprogressive disease, and their role is emerging in patients treated with immunotherapy. Many therapeutic strategies can be adapted in aNSCLC patients with systemic progression to personalize the treatment approach according to re-characterization of the tumors, previous ICI response, and type of progression. This review’s aim is to highlight and discuss the current and potential therapeutic approaches beyond first-line ICI-based therapy in aNSCLC patients based on the pattern of disease progression (oligoprogression versus systemic progression).

【 授权许可】

Unknown